نتائج البحث - Mecide Gharibo

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

    A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myel... حسب Sikander Ailawadhi, Kevin R. Kelly, Robert Vescio, Sundar Jagannath, Jeffrey Wolf, Mecide Gharibo, Taimur Sher, Leyla Bojanini, Maurice Kirby, Asher Chanan‐Khan

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

    A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma حسب Jamie Cavenagh, Heather Oakervee, P Baetiong-Caguioa, Faith E. Davies, Mecide Gharibo, Neil Rabin, Michael R. Kurman, Barbara Novak, Norihiko Shiraishi, Daisuke Nakashima, Shiro Akinaga, Kwee Yong

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies

    Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving... حسب Sarah Nikiforow, Matthew J. Frigault, Noelle V. Frey, Rebecca Gardner, Krishna V. Komanduri, Miguel‐Angel Perales, Partow Kebriaei, Phyllis I. Warkentin, Marcelo C. Pasquini, Joy Lynn Aho, Bruce L. Levine, Helen E. Heslop, Tracey L. Hlucky, Karen Habucky, Mecide Gharibo, Madan Jagasia, Frederick L. Locke

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

    Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier حسب Cecilia Carpio, Réda Bouabdallah, Loïc Ysebaert, Juan‐Manuel Sancho, Gilles Salles, Raúl Córdoba, Antonio Pinto, Mecide Gharibo, Drew Rasco, Carlos Panizo, José A. López-Martín, Armando Santoro, Antonio Salar, Silvia Damian, Alejandro Martı́n, Gregor Verhoef, Éric Van Den Neste, Maria Wang, Suzana S. Couto, Soraya Carrancio, Andrew P. Weng, Xuehai Wang, Frank Schmitz, Xin Wei, Kristen Hege, Matthew Trotter, Alberto Risueño, Tonia J. Buchholz, Patrick R. Hagner, Anita K. Gandhi, Michael Pourdehnad, Vincent Ribrag

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial حسب Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani, Seema Singhal, Ajai Chari, Nizar J. Bahlis, Andrew R. Belch, Amrita Krishnan, Robert Vescio, María‐Victoria Mateos, Amitabha Mazumder, Robert Z. Orlowski, Heather J. Sutherland, Joan Bladé, Emma C. Scott, Albert Oriol, Jesús G. Berdeja, Mecide Gharibo, Don A. Stevens, Richard LeBlanc, Michaël Sébag, Natalie S. Callander, Andrzej Jakubowiak, Darrell White, Javier de la Rubia, Paul G. Richardson, Steen Lisby, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Peter M. Voorhees

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: